全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:M. R. McClung , R. B. Wagman ...
来源:[J].Osteoporosis International(IF 4.039), 2017, Vol.28 (5), pp.1723-1732Springer
摘要:Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bo...
作者:M. R. McClung , K. Lippuner ...
来源:[J].Osteoporosis International(IF 4.039), 2017, Vol.28 (10), pp.2967-2973Springer
摘要:Trabecular bone score (TBS) assesses bone quality in the lumbar spine using dual-energy X-ray absorptiometry (DXA) scans. In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of bone mineral density (BMD). This practical technique may have...
作者:M. R. McClung
来源:[J].Osteoporosis International(IF 4.039), 2016, Vol.27 (5), pp.1677-1682Springer
作者:... P. Chavassieux , M. R. McClung , M. W. Lundy
来源:[J].Osteoporosis International(IF 4.039), 2015, Vol.26 (1), pp.327-337Springer
摘要:Abstract(#br) Summary(#br)This report describes bone safety and histomorphometric data across different dose levels and dosing frequencies of risedronate. Normal bone structure and histomorphometric data were observed, with ongoing bone remodeling and mineralization regardless of...
作者:M. R. McClung , T. Nakamura ...
来源:[J].Osteoporosis International(IF 4.039), 2015, Vol.26 (2), pp.699-712Springer
摘要:Abstract(#br) Summary(#br)Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and increases bone mineral density, with only a transient decrease in bone for...
作者:M. R. McClung , E. M. Lewiecki ...
来源:[J].Osteoporosis International(IF 4.039), 2013, Vol.24 (1), pp.227-235Springer
摘要:Abstract(#br) Summary(#br)In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent reductions in bone turnover markers. Denosumab treatment was well tolerated throughout the 8-year study.(#br) I...
作者:M. R. McClung , J. R. Zanchetta ...
来源:[J].Osteoporosis International(IF 4.039), 2013, Vol.24 (1), pp.293-299Springer
摘要:Abstract(#br) Summary(#br)This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the treatment of postmenopausal osteoporosis. This adds to the range of risedronate dosing options and provide...
作者:M. R. McClung , A. Balske ...
来源:[J].Osteoporosis International(IF 4.039), 2013, Vol.24 (1), pp.301-310Springer
摘要:Abstract(#br) Summary(#br)Bone mineral density response to once weekly delayed-release formulation of risedronate, given before or following breakfast, was non-inferior to that seen with traditional immediate-release risedronate given daily before breakfast. Delayed-release rised...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×